Airsculpt Technologies Inc (AIRS)vsJohnson & Johnson (JNJ)
AIRS
Airsculpt Technologies Inc
$2.54
+2.83%
HEALTHCARE · Cap: $174.25M
JNJ
Johnson & Johnson
$227.35
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 63372% more annual revenue ($96.36B vs $151.82M). JNJ leads profitability with a 21.8% profit margin vs -7.7%. JNJ earns a higher WallStSmart Score of 59/100 (C).
AIRS
Hold36
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$7.04
Current Price
$2.54
$4.50 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$227.35
$67.22 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 200.0% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -14.1% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on EPS Growth, Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : AIRS
The primary concerns for AIRS are Market Cap, Debt/Equity, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.27 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 36/100), backed by strong 21.8% margins. AIRS offers better value entry with a 69.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a leader in the aesthetic medical technology field, recognized for its proprietary AirSculpt® procedure, which offers minimally invasive body contouring solutions while emphasizing patient safety and comfort. The company boasts a growing network of licensed practitioners and a strong focus on technological innovation, positioning itself advantageously in the expanding market for non-invasive cosmetic treatments. By responding to the rising global demand for aesthetic procedures, Airsculpt aims to enhance its market share and diversify its service offerings, thereby fostering both immediate growth and sustainable long-term value for investors.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?